Biospecifics Technologies (BSTC) Reports Q4 EPS of $0.32
Get Alerts BSTC Hot Sheet
Financial Fact:
Operating income (loss): 4.73M
Today's EPS Names:
DSGN, ATRA, CRVS, More
Join SI Premium – FREE
Biospecifics Technologies (NASDAQ: BSTC) reported Q4 EPS of $0.32, versus $0.11 reported last year. Revenue for the quarter came in at $5.6 million, versus $2.3 million reported last year.
"We are seeing strong U.S. commercial growth for XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease, which led to our robust financial results for the quarter. Our net income tripled and our revenues doubled compared to the first quarter of last year," said Thomas L. Wegman, President of BioSpecifics. "Our partner Endo reported that XIAFLEX had a strong first quarter of 2015 with an 114% increase in total vials shipped year-over-year, which was driven by the launch in Peyronie's disease. Endo also continues to show its commitment to advancing the CCH pipeline based on its belief in its vast potential and we look forward to their initiation of the next trial in frozen shoulder syndrome and a Phase 2b trial in cellulite by year-end."
For earnings history and earnings-related data on Biospecifics Technologies (BSTC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- XPeng (XPEV) posts better-than-expected earnings, margin for Q4; stock climbs
- Diversified Energy (DEC) to Acquire Oaktree's Interest in Indigo, Tanos III, East Texas, and Tapstone
- Comtech Telecom (CMTL) Misses Q2 EPS by 5c
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!